You have accessJournal of UrologyProstate Cancer: Epidemiology & Natural History I1 Apr 2014PD31-07 AGENT ORANGE AND LONG-TERM OUTCOMES AFTER RADICAL PROSTATECTOMY Aaron E. Ovadia, Michael R. Abern, William J. Aronson, Christopher J. Kane, Christopher L. Amling, Matthew R. Cooperberg, Stephen J. Freedland, and Martha K. Terris Aaron E. OvadiaAaron E. Ovadia More articles by this author , Michael R. AbernMichael R. Abern More articles by this author , William J. AronsonWilliam J. Aronson More articles by this author , Christopher J. KaneChristopher J. Kane More articles by this author , Christopher L. AmlingChristopher L. Amling More articles by this author , Matthew R. CooperbergMatthew R. Cooperberg More articles by this author , Stephen J. FreedlandStephen J. Freedland More articles by this author , and Martha K. TerrisMartha K. Terris More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.2266AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Currently the evidence linking Agent Orange (AO) to prostate cancer (PC) is limited and conflicting. While studies have demonstrated that AO is a risk factor for adverse pathology and biochemical recurrence, the relationship between AO exposure and long-term outcomes are unknown. METHODS Data from 1,882 men undergoing radical prostatectomy (RP) for PC were analyzed from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Men were classified based on self-reported AO exposure. Predictors of biopsy and pathologic Gleason sum (GS) ≥8, and advanced pathologic stage were determined by logistic regression models adjusted for several pre-operative factors (age, race, clinical stage, PSA, and BMI). Biochemical recurrence (BCR), metastases, and PC specific mortality were determined by Cox proportional hazards adjusted for pre-operative factors as well as center and biopsy GS. RESULTS There were 333 (17.7%) men who had AO exposure. AO exposed men were younger (median 59 vs. 62 years), had lower preoperative PSA (5.8 vs. 6.7 ng/mL) and clinical stage (25 vs. 39% palpable), and higher BMI (28.2 vs. 27.6 kg/m2), all p<0.01. Biopsy GS did not differ. Pathologic GS, rate of positive margins and positive lymph nodes, and extracapsular extension did not differ, however men with AO exposure had a lower rate of seminal vesicle invasion (7.0 vs. 10.9%,p=0.04). At a median follow-up of 85 months, 702 (37.4%) of patients had BCR, 78 (4.1%) had metastases, and 39 (2.1%) died from PC. On multivariable analysis, AO exposure was not associated with BCR, metastases, or PC mortality. CONCLUSIONS In this cohort of PC patients treated with RP, AO exposure was not associated with worse preoperative characteristics such as elevated PSA or biopsy GS, nor was it associated with worse postoperative long-term outcomes of metastases or PC death. Thus, as the data on AO exposed men matures, possible differences in PC outcomes observed in earlier publications are no longer apparent. © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e833-e834 Advertisement Copyright & Permissions© 2014MetricsAuthor Information Aaron E. Ovadia More articles by this author Michael R. Abern More articles by this author William J. Aronson More articles by this author Christopher J. Kane More articles by this author Christopher L. Amling More articles by this author Matthew R. Cooperberg More articles by this author Stephen J. Freedland More articles by this author Martha K. Terris More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...